{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:30:55Z","timestamp":1768789855107,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Neuromuscular disorders (NMDs) are a heterogeneous group of genetic diseases, caused by mutations in genes involved in spinal cord, peripheral nerve, neuromuscular junction, and muscle functions. To advance the knowledge of the pathological mechanisms underlying NMDs and to eventually identify new potential drugs paving the way for personalized medicine, limitations regarding the availability of neuromuscular disease-related biological samples, rarely accessible from patients, are a major challenge.<\/jats:p><jats:p><jats:bold>Aim:<\/jats:bold> We characterized urinary stem cells (USCs) by in-depth transcriptome and protein profiling to evaluate whether this easily accessible source of patient-derived cells is suitable to study neuromuscular genetic diseases, focusing especially on those currently involved in clinical trials.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The global transcriptomics of either native or MyoD transformed USCs obtained from control individuals was performed by RNA-seq. The expression of 610 genes belonging to 16 groups of disorders (<jats:ext-link>http:\/\/www.musclegenetable.fr\/<\/jats:ext-link>) whose mutations cause neuromuscular diseases, was investigated on the RNA-seq output. In addition, protein expression of 11 genes related to NMDs including <jats:italic>COL6A<\/jats:italic>, <jats:italic>EMD<\/jats:italic>, <jats:italic>LMNA<\/jats:italic>, <jats:italic>SMN<\/jats:italic>, <jats:italic>UBA1<\/jats:italic>, <jats:italic>DYNC1H1<\/jats:italic>, <jats:italic>SOD1<\/jats:italic>, <jats:italic>C9orf72<\/jats:italic>, <jats:italic>DYSF<\/jats:italic>, <jats:italic>DAG1<\/jats:italic>, and <jats:italic>HTT<\/jats:italic> was analyzed in native USCs by immunofluorescence and\/or Western blot (WB).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> RNA-seq profile of control USCs shows that 571 out of 610 genes known to be involved in NMDs, are expressed in USCs. Interestingly, the expression levels of the majority of NMD genes remain unmodified following USCs MyoD transformation. Most genes involved in the pathogenesis of all 16 groups of NMDs are well represented except for channelopathies and malignant hyperthermia related genes. All tested proteins showed high expression values, suggesting consistency between transcription and protein representation in USCs.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our data suggest that USCs are human cells, obtainable by non-invasive means, which might be used as a patient-specific cell model to study neuromuscular disease-causing genes and that they can be likely adopted for a variety of <jats:italic>in vitro<\/jats:italic> functional studies such as mutation characterization, pathway identification, and drug screening.<\/jats:p>","DOI":"10.3389\/fphys.2021.716471","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T17:10:16Z","timestamp":1684516216000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Urine-Derived Stem Cells Express 571 Neuromuscular Disorders Causing Genes, Making Them a Potential in vitro Model for Rare Genetic Diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Maria Sofia","family":"Falzarano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Grilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Sabatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Antoniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Selvatici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Al-Khalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gualandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Bicciato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ferlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From Clinical Trials to Clinical Practice: practical Considerations for Gene Replacement Therapy in SMA Type 1.","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1086\/375039","article-title":"Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V.","volume":"72","author":"Antonellis","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"B3","article-title":"Spinal Muscular Atrophy, X-Linked Infantile","author":"Baumbach-Reardon","year":"2008","journal-title":"GeneReviews\u00a7"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1016\/j.yexcr.2008.08.006","article-title":"An enhancer required for transcription of the Col6a1 gene in muscle connective tissue is induced by signals released from muscle cells.","volume":"314","author":"Braghetta","year":"2008","journal-title":"Exp. Cell Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1111\/jcmm.14218","article-title":"A molecular overview of the primary dystroglycanopathies.","volume":"23","author":"Brancaccio","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","article-title":"Gene Therapy for ALS-A Perspective.","volume":"20","author":"Cappella","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.041434","article-title":"Translational medicine in neuromuscular disorders: from academia to industry.","volume":"13","author":"Cowling","year":"2019","journal-title":"Dis. Model Mech."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3390\/ijms21062239","article-title":"Recent Overview of the Use of iPSCs Huntington\u2019s Disease Modeling and Therapy.","volume":"21","author":"Csobonyeiova","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner.","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/ajmg.a.38418","article-title":"Treating pediatric neuromuscular disorders: the future is now.","volume":"176","author":"Dowling","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22315","DOI":"10.1074\/jbc.272.35.22315","article-title":"Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation. Skeletal muscle alpha-dystroglycan is a latent receptor for Vicia villosa agglutinin b4 masked by sialic acid modification.","volume":"272","author":"Ervasti","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1089\/hum.2016.079","article-title":"Duchenne Muscular Dystrophy Myogenic Cells from Urine-Derived Stem Cells Recapitulate the Dystrophin Genotype and Phenotype.","volume":"27","author":"Falzarano","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/jcm8050627","article-title":"Urinary Stem Cells as Tools to Study Genetic Disease: overview of the Literature.","volume":"8","author":"Falzarano","year":"2019","journal-title":"J. Clin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/jcm10040820","article-title":"Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy.","volume":"10","author":"Fortunato","year":"2021","journal-title":"J. Clin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JHD-200427","article-title":"Huntington\u2019s Disease Pathogenesis: two Sequential Components.","volume":"10","author":"Hong","year":"2021","journal-title":"J. Huntingtons Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e002159","DOI":"10.1161\/JAHA.115.002159","article-title":"Toward Personalized Medicine: using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.","volume":"4","author":"Jouni","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neurol.2017.03.015","article-title":"Adult-onset spinal muscular atrophy: an update.","volume":"173","author":"Juntas Morales","year":"2017","journal-title":"Rev. Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13395-016-0103-9","article-title":"Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease.","volume":"6","author":"Kim","year":"2016","journal-title":"Skeletal Muscle"},{"key":"B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1750-1172-8-104","article-title":"Mutations in the PLEKHG5 gene is relevant with autosomal recessive intermediate Charcot-Marie-Tooth disease.","volume":"8","author":"Kim","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jmg.2002.002311","article-title":"Collagen VI related muscle disorders.","volume":"42","author":"Lampe","year":"2005","journal-title":"J. Med. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1093\/hmg\/ddw274","article-title":"Posterior cerebellar Purkinje cells in an SCA5\/SPARCA1 mouse model are especially vulnerable to the synergistic effect of loss of \u03b2-III spectrin and GLAST.","volume":"25","author":"Perkins","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/jid.2010.284","article-title":"Expression of the collagen VI \u03b15 and \u03b16 chains in normal human skin and in skin of patients with collagen VI-related myopathies.","volume":"131","author":"Sabatelli","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fnmol.2019.00297","article-title":"Application of Urine-Derived Stem Cells to Cellular Modeling in Neuromuscular and Neurodegenerative Diseases.","volume":"12","author":"Sato","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s13104-015-1686-7","article-title":"Urine is a novel source of autologous mesenchymal stem cells for patients with epidermolysis bullosa.","volume":"8","author":"Schosserer","year":"2015","journal-title":"BMC Res. Notes"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11042","DOI":"10.1038\/s41598-018-29240-w","article-title":"Urine-derived cells: a promising diagnostic tool in Fabry disease patients.","volume":"8","author":"Slaats","year":"2018","journal-title":"Sci. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/jpm10040178","article-title":"Modelling Neuromuscular Diseases in the Age of Precision Medicine.","volume":"10","author":"Speciale","year":"2020","journal-title":"J. Pers. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/humu.21092","article-title":"Exon skipping-mediated dystrophin reading frame restoration for small mutations.","volume":"30","author":"Spitali","year":"2009","journal-title":"Hum. Mutat."},{"key":"B30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/jcp.20443","article-title":"Ultrastructural defects of collagen VI filaments in an Ullrich syndrome patient with loss of the alpha3(VI) N10-N7 domains.","volume":"206","author":"Squarzoni","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.32098\/mltj.04.2013.08","article-title":"Ultrastructural changes in muscle cells of patients with collagen VI-related myopathies.","volume":"3","author":"Tagliavini","year":"2014","journal-title":"Muscles Ligaments Tendons J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1212\/NXG.0000000000000015","article-title":"Expanding genotype\/phenotype of neuromuscular diseases by comprehensive target capture\/NGS.","volume":"1","author":"Tian","year":"2015","journal-title":"Neurol. Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1684\/epd.2016.0858","article-title":"Spinal muscular atrophy associated with progressive myoclonus epilepsy.","volume":"18","author":"Topaloglu","year":"2016","journal-title":"Epileptic Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3892\/etm.2017.4791","article-title":"Application of urine cells in drug intervention for spinal muscular atrophy.","volume":"14","author":"Zhang","year":"2017","journal-title":"Exp. Ther. Med."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.716471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T17:10:20Z","timestamp":1684516220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.716471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":34,"alternative-id":["10.3389\/fphys.2021.716471"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2021.716471","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"article-number":"716471"}}